Progressive Pulmonary Fibrosis or PPF represents a heterogeneous clinical construct rather than a single disease. Defining it accurately, enrolling the right patients, and selecting meaningful endpoints remain the biggest challenges in translating promising therapies from bench to bedside. This afternoon track explores these complexities, combining clinical insights, trial design lessons, and actionable strategies for real-world development.